Inhalation therapy: New delivery systems

American Journal of Therapeutics

Volumn 8, Issue 5, 2001, Pages 367-381

  Ranade, Vasant V ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aerosols and pulmonary absorption; Aminpglycosides; Beta receptor agonists; Corticosteroids; Dose inhalers; Inhalation actuation; Intranasal

Indexed keywords

AEROSOL; ANIMAL; AREA UNDER THE CURVE; BIOAVAILABILITY; CHEMISTRY; DRUG DELIVERY SYSTEM; FEMALE; HALF LIFE TIME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; NOSE MUCOSA; PHARMACOKINETICS; REVIEW;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; FEMALE; HALF-LIFE; HUMANS; METABOLIC CLEARANCE RATE; NASAL MUCOSA; PHARMACOKINETICS;

EID: 0035464916     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200109000-00010     Document Type: Article

References (5)

1. Chien YW, Chang SF: Intranasal drug delivery for systemic medications. Crit Rev Ther Drug Carrier Syst 1987; 4:67-194.
2. Gonda I, Gipps E: Model of disposition of drugs administered into the human nasal cavity. Pharm Res 1990;7: 69-75.
3. Patton JS: Deep-lung delivery of proteins. Modern Drug Discovery 1998:19-28.
4. Moser AJ, Karam JA, Giurgiu DI, et al: Elevated biliary calmodulin during gallstone formation: the role of bile acids. Dig Dis Sci 1998;43:170-177.
5. Schiffer NGM, Coors-Verhoef J, Merkins FWHM: The nasal mucociliary clearance: relevance to nasal drug delivery. Pharm Res 1991;8:807-814.